If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How does Mounjaro® (tirzepatide) work to improve glycemic control in adults with type 2 diabetes?
Tirzepatide improves glycemic control by enhancing insulin secretion, increasing insulin sensitivity, reducing glucagon levels, delaying gastric emptying, and decreasing food intake.
See important safety information, including boxed warning, in the attached prescribing information.
Mechanism of Action for Glycemic Control
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) for once-weekly, subcutaneous administration.1
Tirzepatide lowers fasting and postprandial glucose concentration in adults with T2D. Tirzepatide improves glycemic control by
- enhancing the first- and second-phase insulin secretion
- increasing insulin sensitivity
- reducing fasting and postprandial glucagon concentrations
- transiently delaying gastric emptying, and
- decreasing food intake.1
Enclosed Prescribing Information
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2023.
Date of Last Review: August 11, 2023